Cantor Fitzgerald Initiates Coverage On Soleno Therapeutics with Overweight Rating, Announces Price Target of $19
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has initiated coverage on Soleno Therapeutics (NASDAQ:SLNO) with an Overweight rating and a price target of $19.
July 11, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soleno Therapeutics has been given an Overweight rating and a price target of $19 by Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Soleno Therapeutics. The price target of $19 suggests a significant upside potential from the current price. This could lead to increased buying interest in the short term, potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100